Skip to main content
  • GLP-1 Drugs Linked to Improved Long-Term Outcomes in Peripheral Artery Disease and Type 2 Diabetes

    GLP-1 receptor agonists were associated with lower rates of death and limb complications in people with both peripheral artery disease (PAD) and type 2 diabetes, according to a new analysis. 

This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Review our Privacy Policy for more details